Could a diabetes drug help beat uterine cancer and spare fertility?
NCT ID NCT07605247
First seen May 25, 2026 · Last updated May 25, 2026
Summary
This study tests whether adding a weight-loss shot (tirzepatide) to standard hormone therapy can better eliminate early-stage uterine cancer or pre-cancer in overweight women. About 30 participants will either get the standard progesterone IUD alone or the IUD plus tirzepatide. The goal is to see if the combination leads to complete cancer clearance at one year while preserving fertility and improving overall health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.